Last update 01 Nov 2024
Guangzhou Doublle Bioproduct Co., Ltd.
Last update 01 Nov 2024
Overview
Tags
Neoplasms
Digestive System Disorders
Urogenital Diseases
Gene therapy
CAR-NK
Monoclonal antibody
Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Related
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
Target |
Mechanism |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest Phase |
First Approval Ctry. / Loc. |
First Approval Date |
一项评价E10A联合帕博利珠单抗对照帕博利珠单抗治疗转移性或不可切除的复发性头颈鳞癌有效性和安全性的随机、开放、多中心II期临床研究
[Translation] A randomized, open-label, multicenter phase II clinical study to evaluate the efficacy and safety of E10A combined with pembrolizumab versus pembrolizumab in the treatment of metastatic or unresectable recurrent head and neck squamous cell carcinoma
一项开放性、剂量递增的I期临床研究，评估E10B在晚期去势抵抗性前列腺癌患者中单次给药的安全性、耐受性和初步疗效
[Translation] An open-label, dose-escalation Phase I study evaluating the safety, tolerability, and preliminary efficacy of a single dose of E10B in patients with advanced castration-resistant prostate cancer
评估 E10H 在晚期消化道癌患者中安全性与耐受性的 I 期临床研究
[Translation] Phase I clinical study to evaluate the safety and tolerability of E10H in patients with advanced gastrointestinal cancer
100 Clinical Results associated with Guangzhou Doublle Bioproduct Co., Ltd.
Login to view more data
Login to view more data
100 Deals associated with Guangzhou Doublle Bioproduct Co., Ltd.
Login to view more data
100 Translational Medicine associated with Guangzhou Doublle Bioproduct Co., Ltd.
Login to view more data
Corporation Tree
Boost your research with our corporation tree data.
login
or
Pipeline
Pipeline Snapshot as of 27 Nov 2024
The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Discovery
1
2
Preclinical
IND Application
1
2
Phase 1 Clinical
Other
2
Login to view more data
Current Projects
Login to view more data
Deal
Boost your decision using our deal data.
login
or
Translational Medicine
Boost your research with our translational medicine data.
login
or
Profit
Explore the financial positions of over 360K organizations with Synapse.
login
or
Grant & Funding(NIH)
Access more than 2 million grant and funding information to elevate your research journey.
login
or
Investment
Gain insights on the latest company investments from start-ups to established corporations.
login
or
Financing
Unearth financing trends to validate and advance investment opportunities.
login
or
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free